5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
July 2024 in “LA CIENCIA AL SERVICIO DE LA SALUD Y NUTRICIÓN” The condition is harmless, doesn't worsen, and needs no invasive treatment.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
7 citations
,
March 2023 in “Lasers in Surgery and Medicine” Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
December 2020 in “Aktualʹnì problemi sučasnoï medicini” Combining betamethasone and PRP injections works best for treating alopecia areata.
March 2022 in “International Journal of Trichology” Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.
August 2021 in “Benha Journal of Applied Sciences” Biotin supplements significantly improve hair loss in people with telegon effluvium who lack biotin.
8 citations
,
August 1987 in “The Journal of Dermatology” BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
3 citations
,
August 2019 in “Medika Tadulako: Jurnal Ilmiah Kedokteran Fakultas Kedokteran dan Ilmu Kesehatan” A 3% hair tonic with bitter melon leaf and carrot extracts boosts hair growth effectively.
7 citations
,
February 2010 in “British Journal of Dermatology” A woman with a rare autoimmune disorder had a blister on her eye and unique immune reaction, which was effectively treated with medication.
1 citations
,
May 2025 in “International Journal of Dermatology” 21 citations
,
December 2014 in “Clinics in dermatology” Squaric acid dibutylester effectively treats alopecia areata.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The herbal hair dye is a safe, effective, and natural alternative to chemical dyes.
March 2026 in “Journal of the European Academy of Dermatology and Venereology” VESALT improves alopecia areata assessment by including non-scalp areas and is reliable and user-friendly.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
June 2022 in “Zenodo (CERN European Organization for Nuclear Research)”
2 citations
,
January 2023 in “BioMed Research International” Beetroot extract nanogel may help treat hair loss caused by testosterone.
April 2026 in “Meditsinskiy sovet = Medical Council” Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
16 citations
,
March 1996 in “PubMed” Switching to twice-weekly betamethasone led to full hair regrowth in 3 months without side effects.
November 2025 in “The Bioscan.” Pix Liquida helped a man recover from patchy hair loss.
2 citations
,
August 2002 in “British Journal of Ophthalmology” Tangent screens help detect visual field defects from vigabatrin.
April 2025 in “Pharmaceutics” Oil A formulation with Baricitinib shows promise for treating alopecia areata by promoting hair growth.
April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
65 citations
,
April 2000 in “The Laryngoscope” Clotrimazole, miconazole, and tolnaftate are likely safe, but gentian violet is risky.
4 citations
,
June 2025 in “Frontiers in Immunology” BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.
4 citations
,
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.